Navigation Links
MabVax Therapeutics Receives Small Business Innovation Research Program Award from the National Cancer Institute
Date:8/17/2010

SAN DIEGO, Aug. 17 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP). Under the SNAP procedures, both initial and follow-on grant requests are submitted and evaluated as one request.  The initial grant award of $150,000 goes to support the manufacture and testing of the company's sarcoma vaccine currently in clinical testing. The follow-on grant application, for more than $1.5 million, can be funded under fast-track procedures following normal NCI reporting and review procedures.

"While the initial grant is modest, it is the critical gateway to substantially more funding that will offset patient and investigator expenses at the 12 investigative sites we have recruited for the Phase 2 clinical trial that is just getting underway," said David Hansen, CEO of MabVax.  He added that "the SNAP program allows the company to submit a grant request that encompasses substantially more of the research project and potentially allows for more rapid funding of the entire grant request."

The sarcoma vaccine grant is intended to support the Phase II clinical trial that will enroll 134 metastatic sarcoma patients in a randomized, multicenter, double-blind study of the trivalent vaccine specifically developed to target and kill residual circulating cancer cells and micrometastases thought to cause recurrent cancer.  In the United States (US), there are approximately 13,200 sarcoma cases diagnosed each year, representing less than 1% of all new cancers.  Prognosis remains poor, with more than 5,200 patients in the US dying of disease each year.  As in other malignancies, disease recurrence and metastasis are common in sarcoma.  Despite undergoing potentially curative surgical resection or combination therapy, the majority of these patients with recurrent sarcoma die as a result of further recurrences.  

The vaccine is designed to instruct the patient's immune system to make antibodies against the three ganglioside antigens present on the surface of sarcoma cells. The antibodies will then seek out and eliminate residual circulating cancer cells and micrometastases. The vaccine was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) where preclinical and early clinical development work was completed in 2009.  MabVax exclusively licensed the sarcoma vaccine, along with additional vaccines targeting other neuroectodermal and epithelial cancers, from MSKCC in 2008.  

Patients who would like additional information are directed to the website clinicaltrials.gov where more details can be found.

About MabVax Therapeutics, Inc.

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. The company was formed to exploit key aspects of the work of Dr. Philip Livingston and colleagues at MSKCC who have developed cancer vaccines against gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence.  The company plans to commercially develop vaccines against several different types of cancer over the coming years.  Concurrently, MabVax is creating a pipeline of monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The company is based in San Diego, CA. MabVax has closed two Series A rounds of venture financing in February 2008 and August of 2009.  


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX to Present at the Immunotherapeutics and Vaccine (IMVAC) Summit
2. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
3. Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea
4. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
5. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Talecris Biotherapeutics to Report Second Quarter 2010 Financial Results
8. Talecris Biotherapeutics Announces Premerger HSR Filing
9. Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management
10. Northwest Biotherapeutics Raises Funding and Proceeds With Balance Sheet Restructuring
11. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... 26, 2017  Genisphere LLC, provider of the ... a collaborative and sponsored research agreement with the ... . The overall goal of the partnership is ... 3DNA designs and formulations after in vivo ... the vasculature as well as inflammatory responses, demonstrating ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. ... , proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the ... 2017. , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... 10 categories with over 30 nominees and well as the first-year award for ... award and the event was hosted by CompanyWeek and Manufacturers Edge, among other ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick Innovative Technology ... of emerging bio and technology start-ups, is hosting “Celebration Friday” (a festive gathering ... will start with libations and networking at 3:30 p.m. at FITCI’s 4539 Metropolitan ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
Breaking Biology News(10 mins):